Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Four-protein complex provides new target for thwarting cancer migration, invasion

The molecular machinery that switches on a gene known to cause breast cancer to spread and invade other organs has been identified by an international team led by scientists at The University of Texas M. D. Anderson Cancer Center. The paper was published Sunday in Nature Cell Biology's advanced online publication.

16 Apr 2010

Regulus Therapeutics' metabolic disease program data presented at Diabetes Keystone Symposium

Regulus Therapeutics Inc. today announced that new data from its metabolic disease program were presented at the "Diabetes" Keystone Symposium held April 12-17 in Whistler, British Columbia. The new pre-clinical research findings showed that therapeutic oligonucleotides targeting microRNA are able to improve insulin resistance and normalize plasma glucose in mouse models of diabetes while having no significant effect on glucose or insulin levels in normal mice.

16 Apr 2010

Current screening methods for FOBT are often not appropriate

More than 75 percent of primary care physicians in the United States who order or perform the fecal occult blood test as a screening option for colorectal cancer perform an in-office test rather than relying on the home-based test, even though the home-based test is more accurate, a study by the Centers for Disease Control and Prevention has found.

16 Apr 2010

Æterna Zentaris receives commitments from institutional investors to purchase $15M in registered direct offering

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has received commitments from institutional investors to purchase US$15 million of securities in a registered direct offering.

16 Apr 2010

Study links cancer growth to sugar-based modification found naturally in the body

Researchers at Drexel University College of Medicine have discovered that a certain type of sugar found naturally in the body is elevated in breast cancer cells and is critical for cancer growth and movement. When researchers reduced and normalized the levels of this sugar, they were able to slow the growth of the cancer cells and block invasion. The findings, published in the March 1 issue of Oncogene, represent a potential new therapeutic target for treating aggressive forms of breast cancer.

15 Apr 2010

Celgene, Agios Pharmaceuticals form global strategic collaboration on targeting cancer metabolism

Celgene Corporation and Agios Pharmaceuticals Inc., a privately-held biotechnology company, today announced the formation of a global strategic collaboration focused on targeting cancer metabolism. The goal of the collaboration is to discover, develop, and deliver novel disease-altering therapies in oncology based on the transformational science of Agios' innovative cancer metabolism research platform. This platform is based on the concept that targeting key metabolic enzymes unique to rapidly proliferating cancer cells can "starve" the cancer.

15 Apr 2010

Foundation Medicine completes $25M Series A financing led by Third Rock Ventures

Foundation Medicine, a personalized cancer medicine company that aims to bring comprehensive cancer genome analysis into routine clinical care, today announced it has completed a $25 million Series A financing led by Third Rock Ventures.

15 Apr 2010

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma and refractory advanced colorectal cancer.

15 Apr 2010

Cell Therapeutics reduces workforce to cut operating costs

Cell Therapeutics, Inc. today announced it has conducted an immediate reduction in force of 36 employees. The Company expects the reduction in force and elimination of previously planned increase in commercial personnel along with a reduction in planned operating expenses to result in savings of approximately $16 million in 2010.

15 Apr 2010

Cancer patients continue to be affected by FN as a result of chemotherapy: Survey

Thirty percent of patients surveyed experienced an infection as a result of chemotherapy, 45 percent of which were associated with neutropenia or febrile neutropenia according to findings from a pan-European patient and nurse survey presented today at the 7th Annual European Oncology Nursing Society Spring Convention.

15 Apr 2010

Investment report on MIPI

StockPreacher.com announces an investment report featuring Molecular Insight Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

15 Apr 2010

AstraZeneca contributes $1M for expansion of Nemours/Alfred I. duPont Hospital for Children

Surrounded by over 100 Nemours Associates, Rich Fante, President, AstraZeneca, U.S., presented Nemours President David J. Bailey, MD, MBA with a ceremonial check for $1 million, announcing AstraZeneca's contribution to the expansion of Nemours/Alfred I. duPont Hospital for Children in Wilmington, Delaware.

15 Apr 2010

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genzyme Corporation today reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an estimated 71 percent of alemtuzumab treated patients remain free of clinically-active disease as much as three years after most patients received their last course of the investigational compound. The data were presented at the American Academy of Neurology annual meeting.

15 Apr 2010

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Pfizer Oncology announced today that it will present new data from the company's pipeline, including two novel, dual PI3K/mTOR inhibitors (PF-04691502 and PKI-587, also known as PF-05212384); crizotinib (PF-02341066), an ALK inhibitor that also inhibits c-MET; and PF-04605412, an anti-α5β1 inhibitor.

15 Apr 2010

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today offered additional commentary, clarifications and insights on yesterday's announcement of its Phase IIa clinical results of Serdaxin® in the treatment of major depressive disorder (MDD).

15 Apr 2010

Comparing effectiveness of PET and other molecular imaging techniques: SNM receives $48,000 AHRQ grant

SNM has been awarded a $48,000 grant from the Agency for Healthcare Research and Quality (AHRQ) to hold a conference to develop research on the comparative effectiveness of positron emission tomography (PET) and other molecular imaging techniques. The primary emphasis will be on the diagnosis and management of cancer patients, but both cardiology and neurology questions will also be addressed.

15 Apr 2010

Ophthalmologist implants radioactive discs in the eyes of children with rare cancer

An ophthalmologist at Washington University School of Medicine in St. Louis is implanting radioactive discs in the eyes of children with a rare cancer in an attempt to save their vision and their eyes.

15 Apr 2010

Synergistic interactions of A2A Agonist and PDE Inhibitors as adjunctive therapy to GC for treating MM

“Glucocorticoids are a key component of combination therapy regimens in multiple myeloma and other hematological cancers. However, glucocorticoid use comes with substantial dose limiting toxicities. The ability to enhance glucocorticoid dependent effects while sparing associated toxicities may have important implications for the treatment of multiple myeloma and other B-cell malignancies”

15 Apr 2010

Targeted therapy MDV3100 is effective for patients with CRPC: Study

An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer, known for its poor prognosis and limited treatment options.

15 Apr 2010

ProCure Proton Therapy Center treats cancer patients with proton therapy technology

The world's first inclined beam treatment room is open and treating patients at the ProCure Proton Therapy Center in Oklahoma City. The third of four treatment rooms at the Oklahoma Center is treating a wide range of tumors with proton therapy, an important alternative to X-ray radiation in treating cancer.

15 Apr 2010

Oncology News and Research

Further Reading

Four-protein complex provides new target for thwarting cancer migration, invasion

Regulus Therapeutics' metabolic disease program data presented at Diabetes Keystone Symposium

Current screening methods for FOBT are often not appropriate

Æterna Zentaris receives commitments from institutional investors to purchase $15M in registered direct offering

Study links cancer growth to sugar-based modification found naturally in the body

Celgene, Agios Pharmaceuticals form global strategic collaboration on targeting cancer metabolism

Foundation Medicine completes $25M Series A financing led by Third Rock Ventures

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

Cell Therapeutics reduces workforce to cut operating costs

Cancer patients continue to be affected by FN as a result of chemotherapy: Survey

Investment report on MIPI

AstraZeneca contributes $1M for expansion of Nemours/Alfred I. duPont Hospital for Children

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Comparing effectiveness of PET and other molecular imaging techniques: SNM receives $48,000 AHRQ grant

Ophthalmologist implants radioactive discs in the eyes of children with rare cancer

Synergistic interactions of A2A Agonist and PDE Inhibitors as adjunctive therapy to GC for treating MM

Targeted therapy MDV3100 is effective for patients with CRPC: Study

ProCure Proton Therapy Center treats cancer patients with proton therapy technology

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News